Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The Impact of Anti-HLA Antibodies on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes After Reduced-Intensity Conditioning Regimens

Marie Y. Detrait, MD, Valerie Dubois, MD, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Nathalie Tedone, CRA, Franck E. Nicolini, MD, PhD, Helene Labussiere, MD, Lilia Gillis, MD, Fiorenza Barraco, MD, Giovanna Cannas, MD, Sophie Ducastelle, MD, Jihane Fattoum, MD, PhD, Xavier Thomas, MD, PhD, Youcef Chelghoum, MD, Mauricette Michallet

Blood (2011) 118 (21): 2038.

https://doi.org/10.1182/blood.V118.21.2038.2038

Published: 2011

Journal Articles

Outcome of High-Risk and Refractory AML/MDS Patients Receiving a FLAMSA Sequential Chemotherapy Regimen Followed by Reduced-Intensity Conditioning (RIC) and Allogeneic Hematopoeitic Stem Cell Transplantation (allo-HSCT)

Marie Y. Detrait, MD, Patrice Chevallier, MD, PhD, Mohamad Sobh, Pharm.M., Thierry Guillaume, Xavier Thomas, MD, PhD, Stephane Morisset, Stat., Nathalie Tedone, CRA, Jacques Delaunay, MD, Franck E. Nicolini, MD, PhD, Helene Labussiere, MD, Sophie Ducastelle, MD, Jihane Fattoum, MD, PhD, Fiorenza Barraco, MD, Giovanna Cannas, MD, Youcef Chelghoum, MD, Mohamad Mohty, Mauricette Michallet

Blood (2011) 118 (21): 1957.

https://doi.org/10.1182/blood.V118.21.1957.1957

Published: 2011

Journal Articles

Highly Significant Impact of HLA-DRB3 and HLA-DRB4 Matching on Different Unrelated Allo-HSCT Outcomes: New Perspectives in the Unrelated Donor Selection

Marie Y. Detrait, MD, Valerie Dubois, MD, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Franck E. Nicolini, MD, PhD, Helene Labussiere, MD, Fiorenza Barraco, MD, Giovanna Cannas, MD, Sophie Ducastelle, MD, Jihane Fattoum, MD, PhD, Xavier Thomas, MD, PhD, Youcef Chelghoum, MD, Nathalie Tedone, CRA, Sylvie Rey, Mauricette Michallet

Blood (2011) 118 (21): 4481.

https://doi.org/10.1182/blood.V118.21.4481.4481

Published: 2011

Journal Articles

Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Hematological Malignancies: Factors Impacting Its Occurrence and Treatment Options for a Better Management,

Mauricette Michallet, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Helene Labussiere, MD, Marie Y. Detrait, MD, Sophie Ducastelle, MD, Fiorenza Barraco, MD, Jihane Fattoum, MD, PhD, Nathalie Tedone, CRA, Youcef Chelghoum, MD, Giovanna Cannas, MD, Xavier Thomas, MD, PhD, Franck E. Nicolini, MD, PhD

Blood (2011) 118 (21): 4093.

https://doi.org/10.1182/blood.V118.21.4093.4093

Published: 2011

Journal Articles

Is the Use of 9/10 HLA Unrelated Donors Still Acceptable in Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies? Comparison with Transplants From 10/10 HLA Unrelated Donors and Siblings

Mauricette Michallet, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Marie Y. Detrait, MD, Helene Labussiere, MD, PhD, Sophie Ducastelle, MD, Fiorenza Barraco, MD, Jihane Fattoum, MD, PhD, Youcef Chelghoum, MD, Xavier Thomas, MD, PhD, Franck E. Nicolini, MD, PhD

Blood (2011) 118 (21): 3087.

https://doi.org/10.1182/blood.V118.21.3087.3087

Published: 2011

Journal Articles

Double Cord Blood Units Allogeneic Transplantation for Hematological Malignancies: Study of the “3 Partners” Matching Variables on Transplant Outcomes

Mauricette Michallet, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Helene Labussiere, MD, Marie Y. Detrait, MD, Franck E. Nicolini, MD, PhD, Sophie Ducastelle, MD, Fiorenza Barraco, MD, Xavier Thomas, MD, PhD, Nathalie Tedone, CRA, Youcef Chelghoum, MD, Jihane Fattoum, MD, PhD, Isabelle Mollet, Valerie Dubois, MD

Blood (2011) 118 (21): 3111.

https://doi.org/10.1182/blood.V118.21.3111.3111

Published: 2011

NARROW

The Impact of Anti-HLA Antibodies on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes After Reduced-Intensity Conditioning Regimens

Outcome of High-Risk and Refractory AML/MDS Patients Receiving a FLAMSA Sequential Chemotherapy Regimen Followed by Reduced-Intensity Conditioning (RIC) and Allogeneic Hematopoeitic Stem Cell Transplantation (allo-HSCT)

Highly Significant Impact of HLA-DRB3 and HLA-DRB4 Matching on Different Unrelated Allo-HSCT Outcomes: New Perspectives in the Unrelated Donor Selection

Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Hematological Malignancies: Factors Impacting Its Occurrence and Treatment Options for a Better Management,

Is the Use of 9/10 HLA Unrelated Donors Still Acceptable in Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies? Comparison with Transplants From 10/10 HLA Unrelated Donors and Siblings

Double Cord Blood Units Allogeneic Transplantation for Hematological Malignancies: Study of the “3 Partners” Matching Variables on Transplant Outcomes

Email alerts

ASH Publications

American Society of Hematology

The Impact of Anti-HLA Antibodies on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes After Reduced-Intensity Conditioning Regimens

Outcome of High-Risk and Refractory AML/MDS Patients Receiving a FLAMSA Sequential Chemotherapy Regimen Followed by Reduced-Intensity Conditioning (RIC) and Allogeneic Hematopoeitic Stem Cell Transplantation (allo-HSCT)

Highly Significant Impact of HLA-DRB3 and HLA-DRB4 Matching on Different Unrelated Allo-HSCT Outcomes: New Perspectives in the Unrelated Donor Selection

Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Hematological Malignancies: Factors Impacting Its Occurrence and Treatment Options for a Better Management,

Is the Use of 9/10 HLA Unrelated Donors Still Acceptable in Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies? Comparison with Transplants From 10/10 HLA Unrelated Donors and Siblings

Double Cord Blood Units Allogeneic Transplantation for Hematological Malignancies: Study of the “3 Partners” Matching Variables on Transplant Outcomes

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only